Skip to main content
. 2023 Oct 24;38(44):e346. doi: 10.3346/jkms.2023.38.e346

Table 3. Incidence of ADEs associated with remdesivir in a population with renal impairment compared with matched controls.

Type of ADEs Total patients No. of patients with ADEs No. of patients with severe ADEs
eGFR ≥ 30 mL/min (n = 500) eGFR < 30 mL/min (n = 125) P value eGFR ≥ 30 mL/min (n = 500) eGFR < 30 mL/min (n = 125) P value
Any ADEs 625 359 (71.8) 100 (80.0) 0.063 80 (16.0) 51 (40.8) < 0.001
Hepatic injury 596 212 (44.5) 59 (49.2) 0.363 16 (3.4) 10 (8.3) 0.017
Renal injury 583 47 (9.8) 22 (21.0) 0.001 10 (2.1) 7 (6.7) 0.020
Hyponatremia 597 87 (18.4) 41 (33.1) < 0.001 7 (1.5) 7 (5.7) 0.013
Hypernatremia 597 41 (8.7) 14 (11.3) 0.369 10 (2.1) 3 (2.4) 0.739
Hypokalemia 597 83 (17.6) 29 (23.4) 0.138 22 (4.7) 11 (8.9) 0.067
Hyperkalemia 597 30 (6.3) 27 (21.8) < 0.001 14 (3.0) 13 (10.5) < 0.001
Hypocalcemia 489 54 (14.3) 22 (20.0) 0.143 2 (0.5) 2 (1.8) 0.220
Hypercalcemia 489 4 (1.1) 3 (2.7) 0.192 0 (0.0) 1 (0.9) 0.225
Anemia 616 153 (31.1) 48 (38.7) 0.106 21 (4.3) 19 (15.3) < 0.001
Thrombocytopenia 616 63 (12.8) 34 (27.4) < 0.001 13 (2.6) 11 (8.9) 0.003
Allergic reaction 622 1 (0.2) 0 (0.0) 1.000 0 (0.0) 0 (0.0) 1.000

Values are presented as number (%).

ADE = adverse drug event, eGFR = estimated glomerular filtration rate.